Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES CREADES IN CONNECTION WITH ITS LISTING ON NASDAQ OMX STOCKHOLM’S MAIN MARKET
Mandate

VINGE ADVISES CREADES IN CONNECTION WITH ITS LISTING ON NASDAQ OMX STOCKHOLM’S MAIN MARKET

December 05, 2013

Creades AB (publ) (NASDAQ OMX First North) has been approved for listing on NASDAQ OMX’s main market. The first day of trading was 6 December 2013.

Vinge’s team primarily consisted of partner Erik Sjöman and associates Jo-Anna Nordström, Christian Lindhé and Rikard Lindahl. Associates Maria Schultzberg and Maria Doeser advised in relation to tax matters.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026

Vinge has advised IK Partners in connection with the acquisition of Selatek

 Vinge has advised IK Partners (“IK”) in connection with IK X Fund’s acquisition of SELATEK Holding AB (“Selatek”), a leading Swedish technical installation platform, from Amplio Private Equity AB and the minority shareholders.
April 20, 2026